SequelSEC

Biomea Fusion, Inc. BMEA

Pharmaceutical Preparations · CIK 0001840439 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$83.51M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Biomea Fusion, Inc. (BMEA) reported net income of -$61.80M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Biomea Fusion, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Biomea Fusion, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$83.51M-$144.07M-$126.14M-$83.63M-$41.67M-$5.33M-$1.20M
Net income-$61.80M-$138.43M-$117.26M-$81.83M-$41.57M-$5.32M-$1.20M
Research & development$61.98M$118.08M$102.55M$62.71M$28.00M$3.67M$1.09M
Weighted-average diluted sharesshares 52.23Mshares 36.11Mshares 34.11Mshares 29.27Mshares 23.86Mshares 10.53MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0Unavailable
Diluted EPS$-1.18$-3.83$-3.44$-2.80$-1.74$-0.51Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$19.33M$25.98M$23.59M$20.92M$13.67M$1.66M$103.00K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Biomea Fusion, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$55.81M$58.28M$176.87M$111.90M$145.74M$61.70M$239.00K
Total assets$58.57M$79.94M$199.93M$129.31M$185.70M$62.53MUnavailable
Current assets$58.05M$68.33M$179.18M$117.82M$176.56M$62.22MUnavailable
Total liabilities$29.02M$28.36M$30.69M$20.77M$6.92M$1.62MUnavailable
Current liabilities$11.10M$21.67M$22.86M$19.10M$4.64M$1.62MUnavailable
Total equity incl. NCI$29.55M$51.57M$169.24M$108.54M$178.78M$5.17M-$21.00K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailable$16.00KUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.23M$12.93M$6.85M$6.83M$1.33M$727.00KUnavailable

Cash flow

Biomea Fusion, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$70.37M-$119.89M-$96.59M-$62.42M-$35.44M-$4.46M-$1.28M
Capital expendituresUnavailable$362.00K$3.37M$1.03M$3.17M$51.00KUnavailable
Investing cash flowUnavailable-$362.00K-$2.22M$27.34M-$33.36M-$51.00KUnavailable
Financing cash flow$67.90M$1.67M$163.80M$1.24M$153.18M$65.97M$1.44M
Net change in cash-$2.47M-$118.59M$64.99M-$33.84M$84.39M$61.46M$161.00K
Stock-based compensation$9.52M$19.09M$14.13M$10.34M$6.23M$322.00KUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Biomea Fusion, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flowUnavailable-$120.26M-$99.96M-$63.45M-$38.61M-$4.51MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio5.23x3.15x7.84x6.17x38.08x38.43xUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BMEA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-24View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-05View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2020-12-31

Difference 55738000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.